Purchases are not available yet. You can browse the site and sign in.
Microdosing With Epilepsy: Seizure Disorder Risks · Microdosing College
Safety
Microdosing With a Seizure Disorder: Why Epilepsy Is a Standard Contraindication
By Microdosing College Editorial·Last updated June 8, 2026·8 min read
Psilocybin seizure disorder epilepsy risk is one of the clearest entries on any honest contraindication list, yet it is often the least explained. Most guides state the rule — "avoid if you have a seizure history" — without unpacking why. This article does that unpacking, so that anyone with epilepsy or a related condition can understand the actual mechanisms and have an informed conversation with their neurologist.
Microdosing College cannot advise you to take or avoid any substance. If you have a seizure disorder, please use our self-screener and speak with a qualified clinician before making any decision.
Why Seizure History Appears on Contraindication Lists
Psilocybin itself — at the doses used in microdosing — has not been shown in human studies to directly trigger seizures in otherwise healthy people. The concern is more nuanced, and it runs along two parallel tracks.
First, the UCSF Translational Psychedelic Research Program lists a history of seizures as a medical contraindication to classic psychedelic use, noting that the altered serotonergic and glutamatergic signalling produced by 5-HT2A agonists like psilocybin could, in a susceptible nervous system, alter the balance between excitation and inhibition. Psilocin — the active metabolite that crosses the blood-brain barrier after the body converts psilocybin — has broad effects on serotonin receptor subtypes, and serotonergic dysregulation has established links to seizure threshold modulation.
Second, and more concretely, people with epilepsy are statistically more likely to be taking medications that interact dangerously with psilocybin, or to be combining substances in ways that create additive risk. The substance itself and the person's full pharmacological picture cannot be separated.
The Lithium Connection: A Well-Documented Danger
Lithium carbonate is prescribed both as a mood stabiliser in bipolar disorder and, less commonly, as an adjunct in epilepsy management. It is also the most widely cited pharmacological reason to avoid psilocybin, and the interaction is directly relevant to seizure risk.
Multiple case reports document seizures occurring when psilocybin (or other serotonergic psychedelics) is combined with lithium. Sarparast et al., writing in Psychiatric Times in their clinician's guide to psilocybin pharmacological interactions, identify the lithium-psychedelic combination as a specific seizure risk, noting that the mechanism is likely related to lithium's narrow therapeutic index and its own pro-convulsant potential at higher plasma levels, compounded by serotonin system activation from the psychedelic.
We cover this interaction in depth in our companion article on psilocybin and lithium seizure risk. If you take lithium for any reason — mood, seizure management, or otherwise — combining it with psilocybin carries a documented risk of seizure that goes beyond speculation.
Tramadol and Threshold Lowering
Tramadol is a widely prescribed analgesic that carries its own independent seizure risk, even without any psychedelic in the picture. It inhibits serotonin and noradrenaline reuptake and, at higher doses or in people with genetic variants affecting CYP2D6 metabolism, can accumulate rapidly and provoke seizures. The combination with psilocybin is therefore a double concern: serotonergic additive effect plus a drug that already lowers the threshold.
Our article on psilocybin and tramadol interaction risk details this further. For anyone with a seizure disorder who also takes tramadol — a common combination in chronic pain with comorbid neurological conditions — the risk stack is particularly serious.
What "Lowering the Seizure Threshold" Actually Means
The phrase appears frequently in clinical literature but deserves a plain explanation. The seizure threshold is the level of neurological excitation required to trigger an abnormal synchronised electrical discharge — a seizure. Everyone has a threshold; in people with epilepsy, that threshold is already lower than in the general population, or it fluctuates more readily.
Factors that lower the threshold further include:
Sleep deprivation — a common and underappreciated risk, relevant because some people report altered sleep with microdosing
Certain serotonergic drugs — which can shift excitatory/inhibitory balance in the cortex
Drug interactions that raise plasma levels of anticonvulsants or create unexpected metabolite accumulation
Stress and autonomic activation — relevant if a microdose produces unexpected anxiety
A person whose epilepsy is well-controlled on medication may have a threshold that sits comfortably above seizure level under normal conditions. Any factor that nudges it downward — even modestly — can bring it to within triggering range. For someone not taking any interacting medication and with well-controlled epilepsy, the absolute risk from psilocybin alone may be low, but the uncertainty is high enough that no responsible clinician or educator should minimise it.
The UCSF guidance cited above is explicit on this point: the concern is not only about direct pharmacological seizure induction but about the interaction of an altered neurological state with an already-compromised seizure threshold.
Anti-Seizure Medications and Psilocybin Metabolism
A further, less-discussed dimension is the effect of anti-seizure medications (ASMs) on psilocybin metabolism — and vice versa. Several commonly prescribed ASMs are potent inducers of cytochrome P450 enzymes, particularly CYP3A4. According to a 2025 systematic review of psilocybin pharmacokinetics in PMC (Pharmacokinetics of Psilocybin: A Systematic Review, PMC 2025), psilocybin undergoes rapid dephosphorylation to psilocin, which is then conjugated via UGT glucuronidation and, to a lesser degree, processed via CYP-mediated oxidation.
Strong CYP inducers (carbamazepine, oxcarbazepine, phenytoin, phenobarbital) could in principle accelerate psilocin clearance, reducing the plasma level and possibly the perceived effect — which might tempt a person to take a higher dose, creating unpredictable exposure. Conversely, some ASMs inhibit certain CYP pathways, which could raise psilocin levels unexpectedly. Neither direction of effect is clinically well-characterised, and that uncertainty itself is a reason for caution.
Valproate, one of the most widely used ASMs, also has serotonergic activity and a seizure-threshold profile that is complex. Combining it with any serotonergic substance is a pharmacological unknown that a neurologist needs to evaluate with full knowledge of the individual's medication regimen.
Practical Guidance: What to Do If You Have a Seizure Disorder
This section is not a recommendation to microdose. It is guidance on how to approach the question responsibly if you are already weighing it.
Do not attempt to self-manage this risk. The interaction variables — seizure type, seizure frequency, current medication, metabolic factors, sleep quality, stress level — are too individual to be covered by any general guide, including this one.
Use the screener first. Our self-screener will flag seizure history as a high-caution factor and provide a structured summary you can bring to a clinical appointment.
Prepare a full medication list. Your neurologist needs to know every substance you take, including supplements, cannabis, and alcohol, to assess interaction risk. Do not omit anything. Our guides on microdosing and cannabis combination risks and microdosing and alcohol risks may be relevant if you use those alongside any prescribed ASM.
Understand what "contraindication" means in context. A contraindication does not always mean a risk is certain or absolute; it means the risk is elevated enough that expert evaluation is mandatory before proceeding. Some people with well-controlled epilepsy and no interacting medications may, after a thorough neurological review, be assessed differently than someone with drug-resistant epilepsy on polypharmacy. Only a neurologist who knows your complete history can make that distinction.
A history of seizures or a diagnosis of epilepsy is a standard, well-founded contraindication to psilocybin microdosing — not because psilocybin is definitively shown to cause seizures in all people, but because:
Serotonergic activity from psilocin can, in susceptible nervous systems, shift excitatory/inhibitory balance toward the seizure threshold.
The most widely reported dangerous interaction — with lithium — carries a documented seizure risk confirmed in case reports and highlighted in clinical pharmacology literature.
Tramadol, another common co-prescription, carries its own independent seizure risk that compounds serotonergic effects.
Anti-seizure medications interact unpredictably with psilocybin metabolism, creating dosing uncertainty in both directions.
The individual variability is too high for any general guide to manage safely without clinician input.
If you have epilepsy and are curious about microdosing, the right starting point is your neurologist — not a harm-reduction article, however carefully written. Please use our self-screener to prepare for that conversation.
Frequently asked
Can psilocybin microdosing trigger a seizure?+
Psilocybin has not been shown to directly trigger seizures in healthy people at microdose levels, but the UCSF Translational Psychedelic Research Program lists a seizure history as a medical contraindication because serotonergic activity can alter excitatory/inhibitory balance in a susceptible nervous system, and because co-used medications such as lithium and tramadol carry documented seizure risk when combined with psilocybin.
Why is lithium especially dangerous when combined with psilocybin?+
Lithium has a narrow therapeutic index and its own pro-convulsant potential at higher plasma levels. Sarparast et al. in Psychiatric Times identify the lithium-psychedelic combination as a specific seizure risk, and multiple case reports document seizures in people who combined lithium with serotonergic psychedelics. This applies regardless of why lithium was prescribed.
Does tramadol lower the seizure threshold?+
Yes. Tramadol inhibits serotonin and noradrenaline reuptake and carries an independent, label-listed risk of seizures — even without any psychedelic involved. Combining it with psilocybin adds serotonergic effects and creates an additive risk that is particularly serious for anyone with a pre-existing seizure disorder.
Can anti-seizure medications affect how the body processes psilocybin?+
Potentially, yes. A 2025 systematic review (PMC) confirms that psilocin is metabolised partly via CYP enzymes. Many anti-seizure medications — including carbamazepine, phenytoin, and phenobarbital — are strong CYP inducers that could alter psilocin plasma levels unpredictably, making accurate dosing impossible and increasing risk in both directions.
Is epilepsy an absolute contraindication, or can it be evaluated case by case?+
Clinically, "contraindication" means the risk is elevated enough to require expert evaluation — it does not always mean the risk is certain or the same for every person. Some people with well-controlled epilepsy and no interacting medications may be assessed differently by a neurologist who knows their full history. No general guide, including this one, can substitute for that individual evaluation.
This guide is general educational information about microdosing, not medical advice and not a recommendation to use any substance. It can't account for your personal health. If you take medication or live with a mental-health condition, speak with a qualified professional before making any decision.
